8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Journal of internal medicine·2018

Net reclassification improvement with serial biomarkers and bed-sided spirometry to early predict the need of organ support during the early post-transplantation in-hospital stay in allogeneic HCT recipients.

Bone marrow transplantation·2018

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.

Biomolecular detection and quantification·2018

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Journal of internal medicine·2017

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Lancet (London, England)·2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody-Related CRS Without Undermining the Anti-Tumor Efficacy.

Cancer science·2026

Ikaros degradation by Iberdomide correlates with normalization of cytokines in Th cells of patients with systemic lupus erythematosus.

Journal of immunology (Baltimore, Md. : 1950)·2026

The Place of Therapeutic Apheresis in Severe Immune-Related Adverse Events: A Scoping Review of Literature.

Journal of clinical apheresis·2026

[Nontuberculous mycobacterial infections in patients with hematologic diseases].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[The role of MAGIC biomarkers in acute GVHD].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Current treatment strategies for diffuse large B-cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease

Related Experiment Videos

Related Concept Videos

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Net reclassification improvement with serial biomarkers and bed-sided spirometry to early predict the need of organ support during the early post-transplantation in-hospital stay in allogeneic HCT recipients.

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody-Related CRS Without Undermining the Anti-Tumor Efficacy.

Ikaros degradation by Iberdomide correlates with normalization of cytokines in Th cells of patients with systemic lupus erythematosus.

The Place of Therapeutic Apheresis in Severe Immune-Related Adverse Events: A Scoping Review of Literature.

[Nontuberculous mycobacterial infections in patients with hematologic diseases].

[The role of MAGIC biomarkers in acute GVHD].

[Current treatment strategies for diffuse large B-cell lymphoma].

8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease

Related Experiment Videos

Related Concept Videos

Related Articles